garetosmab   Click here for help

GtoPdb Ligand ID: 14668

Synonyms: garetosmab-grts | Pasatru® | REGN-2477 | REGN2477
Approved drug
garetosmab is an approved drug
Compound class: Antibody
Comment: Garetosmab (REGN2477) is a fully human anti-activin A (INHBA) monoclonal antibody [4]. The antibody blocks signaling of activins containing the inhibin βα subunit (i.e., activins A, AB, and AC). Peptide sequence matches in a patent search suggests that garetosmab is antibody H4H10446P2 in Regeneron Pharmaceuticals' patent US9718881B2 [3].
References
1. Alharthi MS. (2025)
A Narrative Review of Phase II and III Clinical Trials for the Pharmacological Treatment of Fibrodysplasia Ossificans Progressiva (FOP): Efficacy, Safety, and Challenges in Treatment Strategies.
Drug Des Devel Ther, 19: 8581-8588. [PMID:41017808]
2. Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS et al.. (2023)
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Nat Med, 29 (10): 2615-2624. [PMID:37770652]
3. Gromada J, Latres E, Murphy A, Yancopoulos G, Morton L. (2017)
Anti-Activin A antibodies and uses thereof.
Patent number: US9718881B2. Assignee: Regeneron Pharmaceuticals Inc. Priority date: 30/07/2014. Publication date: 01/08/2017.
4. Vanhoutte F, Liang S, Ruddy M, Zhao A, Drewery T, Wang Y, DelGizzi R, Forleo-Neto E, Rajadhyaksha M, Herman G et al.. (2020)
Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study.
J Clin Pharmacol, 60 (11): 1424-1431. [PMID:32557665]